Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
Support for innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD. Drug targets in the areas of inflammation and proteostasis will be considered high priority.
Característiques principals
The RFP supports:
  • Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME.
  • In vivo testing of novel lead compounds, biologics, repurposed drug candidates in relevant animal models for pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies.
    This RFP does NOT support target identification, target validation, assay development, high-throughput and high-content screening. IND-enabling work is supported through ADDF’s PACT RFP.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: mlopez4@imim.es Ext.: 1576
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Convocatòria (URL)
    https://www.alzdiscovery.org/research-and-grants/funding-opportunities/accelerating-drug-discovery-for-ftd
    Applications:
    https://addf.fluxx.io/
    Dotació
    Budgets averaging $100,000-$150,000 are recommended.
    Durada
    1 year with potential for follow-on funding.
    AVÍS IMPORTANT
    The deadline for applications is August 7, 2020. Submission of a Letter of Intent (LOI) is required on or before July 10, 2020. LOIs are reviewed on a rolling basis and can be submitted any time prior to the deadline.

    Arxius

    Arxiu
    Request for Proposals_ Accelerating Drug Discovery for Frontotemporal Degeneration _ Alzheimer's Drug Discovery Foundation.pdf
    Funding Opportunities_ Application & Funding Policies _ Alzheimer's Drug Discovery Foundation.pdf
    Application Instructions for Core RFPs _ Alzheimer's Drug Discovery Foundation.pdf